Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 15% of the total share amount
Scandion Oncology A/S (“Scandion Oncology”) announces that Saniona has reduced its ownership stake in Scandion Oncology A/S to below 15%. Saniona, together with CEO Nils Brünner and CSO Jan Stenvang initially founded Scandion Oncology A/S in 2017. After the last capital raise in June 2019, Saniona owned approximately 18% of Scandion Oncology. Proceeds from sales of shares will be used to continue Saniona’s advancement of their pipeline, including mid/late-stage clinical trials with Tesomet.
Nils Brünner, CEO of Scandion Oncology says: “We are very grateful for the constructive and valuable support we have received from Saniona in the start-up phase of Scandion Oncology. I wish them all the best luck with developing their pipeline, including drugs that combat obesity, an increasing threat to many people’s health. We are looking forward to a continued collaboration with Saniona”.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on June 22, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.
Codonics orders 8 WasteLog systems
In December 2020, Codonics Inc, Middleburg Heights, Ohio, US and Pharmacolog entered into a long-term partnership agreement for the US market. Prior to that, in the autumn of 2020, the companies had collaborated to integrate the companies' products in order to create an efficient workflow when contr...
Codonics beställer 8 WasteLog system
Codonics Inc, Middleburg Heights, Ohio, US och Pharmacolog ingick i december 2020 ett långsiktigt partneravtal gällande den amerikanska marknaden. Bolagen hade dessförinnan under hösten 2020 samarbetat för att integrera bolagens produkter för att skapa ett effektivt arbetsflöde vid kontroll av retur...
L’équipe Business développement de DEINOVE se renforce pour déployer la stratégie de partenariats de la Société
Hervé ANSANAY, PhD, ancien Directeur du Transfert de technologies et du Business Développement à la SATT AxLR de Montpellier, est nommé Directeur du Business développement Corentin CHABOUD, précédemment responsable des affaires européennes et des financements compétitifs de l’IRT BIOASTER, devient G...
DEINOVE strengthens its Business development team to deploy its partnering strategy
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company pioneering the exploration and exploitation of bacterial biodiversity to address the urgent and global challenge of antimicrobial resistance, announces the strengthening of its Business Development team with the appointment of Hervé AN...